Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions

Covid19

Interventions

DRUG

ensovibep

The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.

Trial Locations (1)

Centre for Human Drug Research, Leiden